Baxter International Inc. - Q1 2005 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2005. Baxter International Inc. operates in three primary segments: Medication Delivery, BioScience, and Renal. The company is an accelerated filer with 620.7 million shares of common stock outstanding as of April 29, 2005.
Key Financial Metrics
| Metric | Q1 2005 | Q1 2004 |
|---|---|---|
| Net Sales | $2,383 million | $2,209 million |
| Net Income | $226 million | $176 million |
| Diluted EPS | $0.36 | $0.28 |
| Cash Flow from Operations | $272 million | ($54 million) |
| Cash and Equivalents | $1,106 million | $646 million |
| Total Debt (Short + Long Term) | $4,599 million | $3,294 million* |
| Gross Margin | 40.7% | 40.4% |
*Note: Q1 2004 debt figures derived from balance sheet data; Q1 2005 reflects a significant increase in short-term debt and current maturities.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 8% year-over-year, driven by an 11% increase in the BioScience segment and 6% growth in both Medication Delivery and Renal segments. International sales grew 13%, aided by a weaker U.S. dollar.
- Profitability: Net income rose 28% to $226 million. Income from continuing operations increased 20% to $224 million.
- Cash Flow: Operating cash flow improved dramatically from a $54 million outflow in Q1 2004 to a $272 million inflow in Q1 2005, primarily due to improved working capital management (receivables and inventories) and the settlement of cross-currency swaps.
- Debt Structure: Short-term debt increased significantly from $207 million to $550 million, and current maturities of long-term debt rose from $154 million to $1,027 million, largely due to the reclassification of notes due in 2006 and increased commercial paper usage.
Guidance, Outlook, and Risks
- Restructuring Outlook: Management expects the 2004 restructuring initiatives to yield savings of $0.20 to $0.25 per diluted share for full-year 2005. Once fully implemented in 2006, total annual savings are anticipated to be $0.30 to $0.35 per diluted share.
- Capital Expenditures: Full-year 2005 capital expenditures are expected to range between $550 million and $600 million.
- Accounting Changes: The company plans to adopt FASB No. 123-R (expensing stock options) on January 1, 2006. Pro forma net income for Q1 2005 under this standard would have been $214 million.
- Legal Contingencies: Significant ongoing litigation includes mammary implant claims, plasma-based therapies (HIV/Hepatitis C), and pricing lawsuits regarding Medicare/Medicaid drugs. Management believes reserves are adequate but acknowledges potential for future charges.
- Regulatory: The company received an FDA warning letter in March 2005 regarding documentation issues at its Tampa facility. Management is addressing these concerns.
Investor Verification Checklist
- Debt Reclassification: Verify the impact of the $873 million reclassification of long-term debt to current maturities on liquidity ratios.
- Restructuring Progress: Confirm the utilization of the $218 million remaining reserve for the 2004 restructuring charge and the timeline for full implementation.
- Legal Reserves: Review the adequacy of reserves for mammary implant and plasma-based therapy litigation, noting the potential for outcomes exceeding current estimates.
- FX Hedging Strategy: Assess the financial impact of the "mirror swap" strategy used to fix the net liability of cross-currency swaps, which increased net interest expense.
- Stock Option Expense: Monitor the impact of the upcoming FASB No. 123-R adoption on future earnings, as pro forma EPS was $0.02 lower than reported in Q1 2005.